<DOC>
	<DOCNO>NCT00004867</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure positron emission tomography may improve ability determine stage esophageal cancer . PURPOSE : This clinical trial study well fludeoxyglucose F 18 positron emission tomography determine tumor stage patient esophageal cancer .</brief_summary>
	<brief_title>Positron Emission Tomography Determining Stage Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary Objective : To evaluate whether FDG-PET image detect lesion would preclude surgery ( esophagectomy ) patient find surgical candidate standard image procedure . Secondary Objective : To use collect data generate hypothesis use future study , type previously undetected lesion FDG-PET image best able identify .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>1 . Patient must â‰¥ 18 year age . 2 . Patient must histologically confirm squamous cell carcinoma adenocarcinoma thoracic esophagus ( great equal 20 cm incisor ) gastroesophageal junction . ( Pathology report must submit ) . 3 . Patient must deem medically fit surgical staging procedure esophagectomy follow thoracic surgeon 's evaluation general medical fitness . 4 . Patient 's clinical staging data ( clinical examination , laboratory test , standard radiological staging assessment ) must obtain within 60 day prior registration must suggest tumor potentially resectable , include tumor stag T13 , N01 , M0 . 5 . Patient must able tolerate FDGPET scan ( e.g. , claustrophobic able lie supine 1.5 hr ) . 6 . Female patient childbearing potential must negative serum urine pregnancy test within 72 hour prior FDGPET . NOTE : Pregnancy test require avoid unnecessary fetal radiation exposure use furosemide contraindicate pregnancy . 7 . Patient patient 's legally acceptable representative must provide sign dated write informed consent prior registration study related procedure . 8 . Patient must provide write authorization allow use disclosure protect health information . NOTE : This may obtain either studyspecific informed consent separate authorization form must obtain patient prior study preregistration . 9 . A cancer survivor eligible provide ALL follow criterion meet document : patient undergone potentially curative therapy prior malignancy evidence prior malignancy least five year ( except completely resect cervical nonmelanoma skin cancer ) patient deem treat physician low risk recurrence prior malignancy . 1 . Patient proximal esophageal cancer ( le 20 cm incisor ) potentially require pharyngolaryngoesophagectomy . 2 . Patient unresectable lesion ( stage M1b , biopsy confirmation distant metastatic disease ; unresectable locoregional invasion , T4 Nx Mx ) . 3 . Patient evidence metastatic disease . NOTE : Obvious metastasis base clinical evaluation include follow : positive cytology pleura , pericardium , peritoneum ; metastasis brain , bone , lung , liver , adrenal ; positive biopsy cytology metastasis supraclavicular lymph node ; involvement tracheobronchial tree ( positive bronchoscopic biopsy overt esophagorespiratory fistula ) . 4 . Patient prior FDGPET scan evaluation esophageal cancer . 5 . Patient uncontrolled diabetes mellitus , evidence fast blood glucose value &gt; 200 mg/dL , within 12 hour FDGPET scan . 6 . Patient receive neoadjuvant chemotherapy and/or radiotherapy PRIOR FDGPET scan perform .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>